Michael P. Kane - Concepedia

Author

Michael P. Kane

Albany College of Pharmacy and Health Sciences ORCID

Also Known As

Andrea N. Traina, Jessica Whitehead, Kane, Michael, M Kane, M P Kane, M. Kane, M. P. KANE, M. P. Kane, M.P. Kane, MICHAEL KANE

157

Publications

2.8K

Citations

H-Index

101

Concepts

All Affiliations

Albany College of Pharmacy and Health Sciences Rutgers Cancer Institute Rutgers, The State University of New Jersey Endocrine Society Albany Medical Center Hospital

About

Michael P. Kane is an author at Albany College of Pharmacy and Health Sciences specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	21	968
2	Health Sciences	5	5	118
3	Engineering	2	2	84
4	Natural Sciences	1	1	41
5	Nursing	1	1	38

Michael P. Kane

Publications

Citations

H-Index

Page 1

	Year	Citations
Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy Hasan Rehman, Ann W. Silk, Michael P. Kane, Journal for ImmunoTherapy of Cancer ImmunologyImmunoeditingPathologyImmunotherapeuticsImmunotherapy	2016	359
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer Anshuman Panda, Janice M. Mehnert, Kim M. Hirshfield, JNCI Journal of the National Cancer Institute	2017	213
Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer Jenna H. Newman, Charles B. Chesson, Nora L. Herzog, Proceedings of the National Academy of Sciences	2019	185
Safety and Efficacy of Exenatide in Combination with Insulin in Patients with Type 2 Diabetes Mellitus Catherine A. Sheffield, Michael P. Kane, Robert Busch, Endocrine Practice Diabetes ManagementInsulin ManagementDiabetesPharmacologyType 2	2008	81
Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Neutropenia during Phase I Development of Liposome-Entrapped Paclitaxel Gerald J. Fetterly, Thaddeus H. Grasela, Jeffrey W. Sherman, Clinical Cancer Research	2008	70
How to ride transport disruption –a sustainable framework for future urban mobility Michael P. Kane, Jake Whitehead Australian Planner Vehicle ElectrificationEngineeringSmart CityTransport SystemsSocial Sciences	2017	65
Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes Robert S. Busch, Michael P. Kane Postgraduate Medicine ObesityMetabolic SyndromeTranslational MedicineDrug ClassesDiabetes Management	2017	58
Colesevelam Hydrochloride-Ezetimibe Combination Lipid-Lowering Therapy in Patients with Diabetes or Metabolic Syndrome and a History of Statin Intolerance Shannon M. Rivers, Michael P. Kane, Robert S. Busch, Endocrine Practice ObesityMetabolic SyndromeLipid DisorderStatin IntoleranceCardiovascular Disease	2007	51
A Glucose Meter Accuracy and Precision Comparison: The FreeStyle Flash Versus the Accu-Chek Advantage, Accu-Chek Compact Plus, Ascensia Contour, and the BD Logic Linda E. Thomas, Michael P. Kane, Gary Bakst, Diabetes Technology & Therapeutics	2008	49
Phase I trial of selenium plus chemotherapy in gynecologic cancers Mihae Song, Muthu N. Kumaran, Murugesan Gounder, Gynecologic Oncology	2018	44

Page 1